Kareem N Rayn1, Jonathan B Bloom1, Samuel A Gold1, Graham R Hale1, Joseph A Baiocco1, Sherif Mehralivand2, Marcin Czarniecki3, Vikram K Sabarwal1, Vladimir Valera1, Bradford J Wood4, Maria J Merino5, Peter Choyke3, Baris Turkbey3, Peter A Pinto6. 1. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 2. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Department of Urology and Pediatric Urology, University Medical Center Mainz, Johannes Gutenberg University Mainz, Mainz, Germany. 3. Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 4. Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 5. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 6. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: pintop@mail.nih.gov.
Abstract
PURPOSE: We examined the additional value of preoperative prostate multiparametric magnetic resonance imaging and transrectal ultrasound/multiparametric magnetic resonance imaging fusion guided targeted biopsy when performed in combination with clinical nomograms to predict adverse pathology at radical prostatectomy. MATERIALS AND METHODS: We identified all patients who underwent 3 Tesla multiparametric magnetic resonance imaging prior to fusion biopsy and radical prostatectomy. The Partin and the MSKCC (Memorial Sloan Kettering Cancer Center) preradical prostatectomy nomograms were applied to estimate the probability of organ confined disease, extraprostatic extension, seminal vesicle invasion and lymph node involvement using transrectal ultrasound guided systematic biopsy and transrectal ultrasound/multiparametric magnetic resonance imaging fusion guided targeted biopsy Gleason scores. With radical prostatectomy pathology as the gold standard we developed multivariable logistic regression models based on these nomograms before and after adding multiparametric magnetic resonance imaging to assess any additional predictive ability. RESULTS: A total of 532 patients were included in study. When multiparametric magnetic resonance imaging findings were added to the systematic biopsy based MSKCC nomogram, the AUC increased by 0.10 for organ confined disease (p <0.001), 0.10 for extraprostatic extension (p = 0.003), 0.09 for seminal vesicle invasion (p = 0.011) and 0.06 for lymph node involvement (p = 0.120). Using Gleason scores derived from targeted biopsy compared to systematic biopsy provided an additional predictive value of organ confined disease (Δ AUC 0.07, p = 0.003) and extraprostatic extension (Δ AUC 0.07, p = 0.048) at radical prostatectomy with the MSKCC nomogram. Similar results were obtained using the Partin nomogram. CONCLUSIONS: Magnetic resonance imaging alone or in addition to standard clinical nomograms provides significant additional predictive ability of adverse pathology at the time of radical prostatectomy. This information can be greatly beneficial to urologists for preoperative planning and for counseling patients regarding the risks of future therapy.
PURPOSE: We examined the additional value of preoperative prostate multiparametric magnetic resonance imaging and transrectal ultrasound/multiparametric magnetic resonance imaging fusion guided targeted biopsy when performed in combination with clinical nomograms to predict adverse pathology at radical prostatectomy. MATERIALS AND METHODS: We identified all patients who underwent 3 Tesla multiparametric magnetic resonance imaging prior to fusion biopsy and radical prostatectomy. The Partin and the MSKCC (Memorial Sloan Kettering Cancer Center) preradical prostatectomy nomograms were applied to estimate the probability of organ confined disease, extraprostatic extension, seminal vesicle invasion and lymph node involvement using transrectal ultrasound guided systematic biopsy and transrectal ultrasound/multiparametric magnetic resonance imaging fusion guided targeted biopsy Gleason scores. With radical prostatectomy pathology as the gold standard we developed multivariable logistic regression models based on these nomograms before and after adding multiparametric magnetic resonance imaging to assess any additional predictive ability. RESULTS: A total of 532 patients were included in study. When multiparametric magnetic resonance imaging findings were added to the systematic biopsy based MSKCC nomogram, the AUC increased by 0.10 for organ confined disease (p <0.001), 0.10 for extraprostatic extension (p = 0.003), 0.09 for seminal vesicle invasion (p = 0.011) and 0.06 for lymph node involvement (p = 0.120). Using Gleason scores derived from targeted biopsy compared to systematic biopsy provided an additional predictive value of organ confined disease (Δ AUC 0.07, p = 0.003) and extraprostatic extension (Δ AUC 0.07, p = 0.048) at radical prostatectomy with the MSKCC nomogram. Similar results were obtained using the Partin nomogram. CONCLUSIONS: Magnetic resonance imaging alone or in addition to standard clinical nomograms provides significant additional predictive ability of adverse pathology at the time of radical prostatectomy. This information can be greatly beneficial to urologists for preoperative planning and for counseling patients regarding the risks of future therapy.
Authors: Dirk Boehmer; Philippe Maingon; Philip Poortmans; Marie-Hélène Baron; Raymond Miralbell; Vincent Remouchamps; Christopher Scrase; Alberto Bossi; Michel Bolla Journal: Radiother Oncol Date: 2006-06-22 Impact factor: 6.280
Authors: Felix Preisser; Michele Marchioni; Sebastiano Nazzani; Marco Bandini; Zhe Tian; Raisa S Pompe; Francesco Montorsi; Fred Saad; Firas Abdollah; Thomas Steuber; Hans Heinzer; Hartwig Huland; Markus Graefen; Derya Tilki; Pierre I Karakiewicz Journal: Eur Urol Focus Date: 2018-01-03
Authors: Andrew J Stephenson; Peter T Scardino; James A Eastham; Fernando J Bianco; Zohar A Dotan; Paul A Fearn; Michael W Kattan Journal: J Natl Cancer Inst Date: 2006-05-17 Impact factor: 13.506
Authors: Liza Quintana; Ashley Ward; Sean J Gerrin; Elizabeth M Genega; Seymour Rosen; Martin G Sanda; Andrew A Wagner; Peter Chang; William C DeWolf; Huihui Ye Journal: Urology Date: 2016-03-02 Impact factor: 2.649
Authors: Soroush Rais-Bahrami; M Minhaj Siddiqui; Baris Turkbey; Lambros Stamatakis; Jennifer Logan; Anthony N Hoang; Annerleim Walton-Diaz; Srinivas Vourganti; Hong Truong; Jochen Kruecker; Maria J Merino; Bradford J Wood; Peter L Choyke; Peter A Pinto Journal: J Urol Date: 2013-05-29 Impact factor: 7.450
Authors: Michael Mullerad; Hedvig Hricak; Liang Wang; Hui-Ni Chen; Michael W Kattan; Peter T Scardino Journal: Radiology Date: 2004-05-27 Impact factor: 11.105
Authors: Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton Journal: Lancet Date: 2017-01-20 Impact factor: 79.321
Authors: Jonathan B Bloom; Graham R Hale; Samuel A Gold; Kareem N Rayn; Clayton Smith; Sherif Mehralivand; Marcin Czarniecki; Vladimir Valera; Bradford J Wood; Maria J Merino; Peter L Choyke; Howard L Parnes; Baris Turkbey; Peter A Pinto Journal: J Urol Date: 2019-01 Impact factor: 7.450
Authors: Dennie Meijer; Pim J van Leeuwen; Maarten L Donswijk; Thierry N Boellaard; Ivo G Schoots; Henk G van der Poel; Harry N Hendrikse; Daniela E Oprea-Lager; André N Vis Journal: BJU Int Date: 2021-06-16 Impact factor: 5.969
Authors: Zachary A Glaser; Jennifer B Gordetsky; Sejong Bae; Jeffrey W Nix; Kristin K Porter; Soroush Rais-Bahrami Journal: Urol Oncol Date: 2019-09-05 Impact factor: 3.498
Authors: Andreas G Wibmer; Michael W Kattan; Francesco Alessandrino; Alexander D J Baur; Lars Boesen; Felipe Boschini Franco; David Bonekamp; Riccardo Campa; Hannes Cash; Violeta Catalá; Sebastien Crouzet; Sounil Dinnoo; James Eastham; Fiona M Fennessy; Kamyar Ghabili; Markus Hohenfellner; Angelique W Levi; Xinge Ji; Vibeke Løgager; Daniel J Margolis; Paul C Moldovan; Valeria Panebianco; Tobias Penzkofer; Philippe Puech; Jan Philipp Radtke; Olivier Rouvière; Heinz-Peter Schlemmer; Preston C Sprenkle; Clare M Tempany; Joan C Vilanova; Jeffrey Weinreb; Hedvig Hricak; Amita Shukla-Dave Journal: Cancers (Basel) Date: 2021-05-27 Impact factor: 6.639